To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Heavy chainA heavy chain is the large polypeptide subunit of a protein complex, such as a motor protein (e.g. myosin, kinesin, or dynein) or antibody (or immunoglobulin). A typical antibody is composed of two immunoglobulin (Ig) heavy chains and two Ig light chains. Several different types of heavy chain exist that define the class or isotype of an antibody. These heavy chain types vary between different animals. All heavy chains contain a series of immunoglobulin domains, usually with one variable (IgV) domain that is important for binding antigen and several constant (IgC) domains. Product highlight
In mammalsClassesThere are five types of mammalian immunoglobulin heavy chain: γ, δ, α, μ and ε.[1] They define classes of immunoglobulins.
RegionsEach heavy chain has two regions:
In fishJawed fish appear to be the most primitive animals that are able to make antibodies like those described for mammals.[3] However, fish do not have the same repertoire of antibodies that mammals possess.[4] Three distinct Ig heavy chains have so far been identified in bony fish.
Similar to the situation observed for bony fish, three distinct Ig heavy chain isotypes have been identified in cartilaginous fish. With the exception of IgM, these Ig heavy chain isotypes appear to be unique to cartilaginous fish and are designated IgM, IgW (also called IgX or IgNARC) and IgNAR.[8] References
|
|||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Heavy_chain". A list of authors is available in Wikipedia. |
- Rational_Emotive_Behavior_Therapy
- New chemical tool developed for infection research - Researchers present a new molecule for visualising the sphingomyelin metabolism - This offers prospects for innovative therapeutic approaches
- SIRION Biotech is now part of Revvity
- Adriana_Iliescu
- AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT - Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases